Stryker (NYSE:SYK) today announced it completed the acquisition of Cerus Endovascular. The financial details of the deal were not disclosed.
Cerus Endovascular designs and develops neurointerventional devices for the treatment of intracranial aneurysms. Cerus Endovascular’s CE marked products, the Contour Neurovascular system and Neqstent could assisted flow diverter, will expand Stryker’s portfolio of aneurysm treatment solutions.
Most recently, Cerus Endovascular was granted IDE approval from the FDA for a clinical trial of its Contour Neurovascular system in April. The company designed it with a fine mesh brain to target the neck of the aneurysm away from the vulnerable dome. It self-anchors the system for stability and is re-sheathable for precise placement, and the sizing criteria are less restrictive because of the deployment across the neck. The system also received FDA breakthrough designation in February.
“The acquisition of Cerus Endovascular is highly complementary to Stryker’s Neurovascular business, and strengthens our hemorrhagic portfolio globally,” Jim Marucci, president of Stryker’s neurovascular division, said in a news release. “We look forward to working with the Cerus team to deliver on our mission of making healthcare better. Together, we will enable physicians to treat a broader range of aneurysms.”
